Exagen
About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Employees: 179
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,300% more call options, than puts
Call options by funds: $14K | Put options by funds: $1K
59% more capital invested
Capital invested by funds: $12.4M [Q2] → $19.8M (+$7.33M) [Q3]
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 33 [Q2] → 34 (+1) [Q3]
2.53% less ownership
Funds ownership: 39.31% [Q2] → 36.77% (-2.53%) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for XGN.
Financial journalist opinion
Based on 4 articles about XGN published over the past 30 days
